Development of Real-Time PCR Assays for Genotyping of *Chlamydia trachomatis*®

Hamid Jalal,1* Hannah Stephen,1 Sarah Alexander,2 Christopher Carne,3 and Christopher Sonnex3

Clinical Microbiology & Public Health Laboratory, Box 236, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QW, United Kingdom1; Sexually Transmitted Bacteria Reference Laboratory, Centre for Infection, 61 Colindale Avenue, London NW9 5HT, United Kingdom2; and Department of Genitourinary Medicine, Clinic 1A, Box 38, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, United Kingdom3

Received 27 February 2007/Returned for modification 27 March 2007/Accepted 30 May 2007

We have developed and validated a nested real-time PCR (NRT-PCR) for the genotyping of *Chlamydia trachomatis* and used it specifically for the typing of either eight genovars from D to K or three genovars of lymphogranuloma venereum (LGV). The 11 probes used in the NRT-PCR correctly identified the DNA from D to K and LGV reference strains and did not cross-react with the DNA from 26 strains representing the bacterial pathogens and commensals of the oropharynx, genital tract, and rectum. The NRT-PCR had a 95% probability of detection at four genome copies (confidence interval, three to six copies) of *C. trachomatis* per reaction. One hundred cervical and urethral swab specimens containing *C. trachomatis* DNA from 63 women and 37 men were used to validate the method. The results from the NRT-PCR and the DNA sequencing of amplicons generated from the *omp1* gene showed 100% correlation for these samples. The assay also identified the LGV-II genotype in 24 of 48 rectal swab specimens containing *C. trachomatis* DNA that were obtained from men having sex with men. The Sexually Transmitted Bacteria Reference Laboratory, London, independently confirmed these results using group-specific LGV real-time PCR and restriction fragment length polymorphism analysis. Compared with the NRT-PCR, non-NRT-PCR was found to be less sensitive: it typed *C. trachomatis* DNA in only 80% of the genital samples and 90% of the rectal swab samples. This is the first successful demonstration of the use of real-time PCR for the genotype-specific typing of *C. trachomatis* strains that cause sexually transmitted diseases.

*Chlamydia trachomatis* infection is a significant global health problem. *C. trachomatis* is the causative agent of trachoma and sexually transmitted diseases (STDs), i.e., lymphogranuloma venereum (LGV) and other genital manifestations. Trachoma is the second major cause of blindness (cataract is the first) and affects 6 million people worldwide (17), while the estimated global incidence of STDs caused by *C. trachomatis*, is about 92 million (19). This organism is an intracellular bacterium, and its different genovars produce specific clinical manifestations; i.e., types A, B, Ba, and C cause trachoma, types LGV-I, -II, and -III cause LGV, and types D to K cause ocurolgenital diseases (14). Trachoma is hyperendemic in many of the poorest areas of Africa, Asia, Central and South America, Australia, and the Middle East (17). The prevalence of LGV is highest in the tropics and subtopics (14). A number of LGV outbreaks among men who have sex with men have been reported recently in different western countries (3, 11, 18). Types D to K are prevalent worldwide (19). Due to extensive genetic diversity between different genovars, together with their distinct geographical distribution and clinical manifestations, a better appreciation of the molecular epidemiology of *C. trachomatis* infection is crucial to control this infection. The genotyping of *C. trachomatis* is also important for understanding the pathogenesis of infection and sequelae of the infection, for monitoring therapy and contact tracing, and for the development of a vaccine.

The genotyping of *C. trachomatis* is based mainly on nested PCR targeting of the *omp1* gene. The amplicons are being used for typing by restriction fragment length polymorphism (RFLP) analysis (2, 7, 9, 12), DNA sequencing (1, 8, 15, 21), reverse line blot hybridization (10, 16, 20), and oligonucleotide reverse line blot hybridization (10, 16, 20), and oligonucleotide restriction fragment length polymorphism analysis. Compared with the NRT-PCR, non-NRT-PCR was found to be less sensitive: it typed *C. trachomatis* DNA in only 80% of the genital samples and 90% of the rectal swab samples. This is the first successful demonstration of the use of real-time PCR for the genotype-specific typing of *C. trachomatis* strains that cause sexually transmitted diseases.

**MATERIALS AND METHODS**

**Bacterial strains.** Fourteen isolates representing all the genovars of *C. trachomatis* and 26 bacterial isolates representing the pathogenic bacteria and commensals of the oropharynx, genital tract, and rectum were used to investigate the specificities of primers and probes. The identities of these organisms are shown in Tables 1 and 2 in a previous publication (5), while their culture and the extraction of DNA from bacterial suspensions were performed as described in the same paper (5). The ability of the NRT-PCR to generate correct results from mixed infections was investigated by testing 11 pools of DNA from different strains of *C. trachomatis*. The pools of 100-μl volumes were prepared by mixing 1 ng of DNA from one strain and 100 ng of DNA from each of the other two or three strains according to the format of each assay (Fig. 1). The composition of...
each pool is described below. Pool 1 contained 1 ng DNA from genotype D and 100 ng DNA from each of genotypes E, H, and I. Pool 2 contained 1 ng DNA from genotype E and 100 ng DNA from each of genotypes D, H, and I. Pool 3 contained 1 ng DNA from genotype H and 100 ng DNA from each of genotypes D, E, and I. Pool 4 contained 1 ng DNA from genotype I and 100 ng DNA from each of genotypes D, E, and H. Pool 5 contained 1 ng DNA from genotype F and 100 ng DNA from each of genotypes G, J, and K. Pool 6 contained 1 ng DNA from genotype G and 100 ng DNA from each of genotypes F, J, and K. Pool 7 contained 1 ng DNA from genotype J and 100 ng DNA from each of genotypes F, G, and K. Pool 8 contained 1 ng DNA from genotype K and 100 ng DNA from each of genotypes F, G, and J. Pool 9 contained 1 ng DNA from genotype LGV-I and 100 ng DNA from each of genotypes LGV-II and LGV-III. Pool 10 contained 1 ng DNA from genotype LGV-II and 100 ng DNA from each of genotypes LGV-I and LGV-III. Pool 11 contained 1 ng DNA from genotype LGV-III and 100 ng DNA from each of genotypes LGV-I and LGV-II.

Validation panel. The validation panel included DNA from 100 anonymous samples, consisting of urethral swab specimens from 37 men and both urethral and cervical swab specimens in a single tube from 63 women. These samples were collected as described previously (4). DNA was extracted using the MagNA Pure LC total nucleic acid isolation kit and MagNA Pure LC Robot, according to the manufacturer’s protocol, Roche Molecular Systems, Inc., CA (4). C. trachomatis genotyping was performed by DNA sequencing of amplicons generated by nested PCR from the omp1 gene (6). All samples were coded, and genotyping results were masked before validation experiments. The samples were tested by both NRT-PCR and NNRT-PCR.

Rectal swab specimens. The Sexually Transmitted Bacteria Reference Laboratory (STBRL), London, United Kingdom, provided an aliquot from each of 48 anonymous rectal swab samples from men who have sex with men. These samples were collected by different regional laboratories in the United Kingdom and sent to the STBRL for epidemiological investigations for LGV. The STBRL detected C. trachomatis DNA in rectal swab samples using an in-house real-time PCR assay which targeted the cryptic plasmid. LGV DNA was detected in 24 of 48 samples using a previously described LGV group-specific real-time PCR assay (LGV-PCR) (13). In accordance with their policy, the STBRL performed RFLP analysis only on LGV-PCR-positive samples, as described previously (9). RFLP analysis identified LGV-II DNA in 21 of 24 samples but failed for the remaining 3. The STBRL performed all of the above-described experiments as part of a routine diagnostic service. The aliquots of samples were coded before being sent to our laboratory. DNA from rectal swab samples was extracted using an XTR1-1 kit (Sigma-Aldrich, Steinheim, Germany) and the CAS-1820 X-Tractor gene automated DNA/RNA extraction system (Corbett Robotics, Australia), according to the manufacturer’s protocol. All samples were tested with both NRT-PCR and NNRT-PCR.

Nestec PCR. (i) First round of block-based PCR. Block-based PCR was performed with a 50-μl volume containing 5 μl of DNA from a clinical sample, a bacterial isolate, or a pool of DNA from different strains of C. trachomatis; a 200 μM concentration of each deoxynucleoside triphosphate; 25 pmol of each primer (P1 and P2); 4 mM MgCl2; 5 μl of 10× PCR buffer; and 1.5 units of recombinant Taq DNA polymerase (Invitrogen Life Technologies, Paisley, United Kingdom). DNAs from different strains of C. trachomatis were used as positive controls, according to the format of the assay, and nuclease-free water was used as a negative control for amplification. Samples and controls were denatured at 95°C for 3 min, followed by 20 cycles of amplification in a PTC-200 Peltier thermal cycler (Genetic Research Instrumentation Ltd., Essex, United Kingdom). Each cycle consisted of denaturation at 95°C for 10 seconds, annealing

![Diagram of PCR assays](http://jcm.asm.org/)

FIG. 1. Schematic representations of the formats of the NRT-PCR (A) and NNRT-PCR (B) assays. The sequences and nucleotide positions of primers and probes are shown in Table 1.
ing of primers at 50°C for 10 seconds, and extension at 72°C for 1 min, followed by a final extension at 72°C for 7 min.

(ii) Second round of real-time PCR. Real-time PCR was performed using a Rotorgene 3000 apparatus (Corbett Robotics, Australia) essentially as described previously but with a few modifications (5). A pair of primers, P3 and P4, and three to four labeled probes in TaqMan format were used for each component of the assay (Fig. 1A). PCR was performed in a 25-μl volume containing 1 μl of amplicons generated by blocked-base PCR, 12.5 μl of Platinum Quantitative PCR SuperMix-UDG (Invitrogen Life Technologies, Paisley, United Kingdom), 6.25 pmol of each primer, and 2.5 pmol of each probe. The amplification reaction profile included heating at 50°C for 2 min and at 95°C for 2 min followed by 30 cycles of 95°C for 1 second and 55°C for 90 seconds. The signal was acquired at 55°C during each cycle. All primers and probes were synthesized by Metabion International AG, Germany, except the MGB-labeled probes, which were synthesized by Applied Biosystems, Cheshire, United Kingdom (Table 1). The two-step nested PCR, as used in this study and in previously published studies (1, 7, 8, 9, 10, 15, 20, 21, 22), carries an inherent risk of contaminating equipment and laboratory environment. Stringent physical separation of different steps in the assays, namely, the use of dedicated equipment for each step, a one-way flow of work from extraction to amplification, meticulous techniques to prevent the production of aerosols from tubes containing amplicons, and filtered tips avoided this problem.

NNRT-PCR. NNRT-PCR was performed as the second round of the NRT-PCR, with two changes. The reaction mixture contained 5 μl of DNA from either a clinical sample or a bacterial isolate instead of 1-μl amplicons, and the number of amplification cycles was increased from 30 to 50. Different combinations of primers and probes were used for NNRT-PCR assays. These combinations are shown in Fig. 1B. The sequences of all primers and probes used in this study are shown in Table 1.

RESULTS

Analytic sensitivity. The lower limit of detection for NNRT-PCR was determined by testing a dilution series using C. trachomatis genotype E (ATCC code, VR-348B) at the following concentrations: 32, 16, 8, 4, 2, and 1 genome copies per reaction mixture. Each concentration was tested in 10 replicates, and Probit analysis of the result was carried out using StatsDirect version 2.4.1. According to Probit analysis, the assay has a 95% probability of detection with four genome copies (confidence interval, three to six copies) of C. trachomatis per reaction. For DNA from cultures of genovar E, the sensitivity of NNRT-PCR was comparable with that of NRT-PCR. However, the cycle threshold value for each of the 10-fold serial dilutions, ranging from 5,000 to 5 genome copies per reaction mixture, as determined by NNRT-PCR was 17 to 18 cycles higher than that of NRT-PCR.

Analytic specificity. The primers and probes used in this study did not cross-react with the DNA from any of the patho-
genic bacteria or commensals tested from the oropharynx, genital tract, and rectum. The primers amplified DNA from all strains of *C. trachomatis*, and the probes correctly identified their respective genovars without any cross-reactivity. Examples of the results for NRT-PCR are shown in Fig. 2 and 3. All genotypes were also correctly identified within pools containing various concentrations of DNA from different strains of *C. trachomatis*.

**Validation panel.** Using DNA sequencing as a gold standard, NRT-PCR typed all of 100 samples in the validation panel correctly. NNRT-PCR was unable to genotype *C. trachomatis* DNA in 20 of the same 100 samples. However, the typing results generated by this assay from the remaining 80 samples were correct. The results are summarized in Table 2.

**Rectal swab samples.** NRT-PCR typed *C. trachomatis* DNA in all 48 rectal swab samples. NNRT-PCR was able to do it in only 43 of these samples. Of those that contained LGV DNA, 22 were correctly identified by NNRT-PCR, and all 24 were identified by NRT-PCR. The results are summarized in Table 2.

**DISCUSSION**

The *omp1* gene is the most variable genetic marker of *C. trachomatis* for epidemiological investigations. It has regions of highly conserved and highly variable nucleotide sequences, and this characteristic has been exploited by various molecular techniques for the genotyping of *C. trachomatis* (1, 2, 16, 22). We designed primers from the conserved regions and probes

**TABLE 2. Comparison of NRT-PCR and NNRT-PCR assays for genotyping of *C. trachomatis***

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Validation panel</th>
<th>Rectal swabs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DNA sequencing</td>
<td>NRT-PCR</td>
</tr>
<tr>
<td>D</td>
<td>19</td>
<td>19</td>
</tr>
<tr>
<td>E</td>
<td>38</td>
<td>38</td>
</tr>
<tr>
<td>F</td>
<td>24</td>
<td>24</td>
</tr>
<tr>
<td>G</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>H</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>I</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>J</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>K</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>LGV-I</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LGV-II</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>LGV-III</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>
from the variable regions of the *omp1* gene. The primers amplified DNA from all genovars of *Chlamydia trachomatis*, including genovars for trachoma. The probes were designed only for genovars D to K and LGV. Our primers and probes did not cross-react with DNA from the pathogens or commensals of the oropharynx, genital tract, and rectum samples. After extensive trials and errors in combining probes for different types, we describe here a highly sensitive and specific NRT-PCR for the genotyping of *Chlamydia trachomatis*.

In recent publications, 9% (10) and 13% (21) of clinical samples were reported to contain DNA from more than one genovar of *Chlamydia trachomatis*. RFLP analysis and sequencing are unable to identify genotypes in such samples without cloning of amplicons. Such cloning is a laborious, time-consuming, and cumbersome technique unsuitable for epidemiological studies. Reverse line blot hybridization (10, 16, 21) and our NRT-PCR assays, due to the use of a specific probe for each genovar, are ideal techniques for typing *Chlamydia trachomatis* in clinical samples containing DNA from multiple genovars. Unfortunately, such samples were not available for this study. However, experiments performed on artificially mixed DNA from different genotypes demonstrated the ability of NRT-PCR to type multiple genotypes accurately in an amplification reaction.

Regardless of the nature of the techniques, most published methods use two-step nested PCR for the genotyping of *Chlamydia trachomatis* (1, 7, 8, 9, 10, 15, 20, 21, 22). In line with these methods, we have now developed for the same purpose a two-step NRT-PCR. Its sensitivity for chlamydia in culture was the same as that of NNRT-PCR, while its sensitivity with both genital and rectal swabs was superior to that of NNRT-PCR, which typed for 80% of the genital samples and 90% of the rectal samples. NRT-PCR produced peaks which were easy to interpret even from samples with low levels of DNA. The peaks generated by NNRT-PCR from such samples were very close to the threshold of detection and often difficult to interpret.

Real-time PCR, without two steps for nesting, could be fully automated by the use of robotic liquid handling, but two-step PCR makes automation difficult. Further work is needed to convert NRT-PCR to a single-tube nested amplification. In conclusion, the present study has demonstrated the feasibility of using real-time PCR for genotyping the strains of *Chlamydia trachomatis* that cause STDs. Such assays could be adapted to the needs of different epidemiological projects, i.e., the genotyping of *Chlamydia trachomatis* strains that cause LGV or the identification of genotypes D to K in clinical samples. A similar assay could be developed to type the strains of *Chlamydia trachomatis* that cause trachoma.

ACKNOWLEDGMENTS

We are grateful to Ian Silver and Maria Erechinska for their suggestions to improve the presentation of this article. We are also grateful to the STBRL for providing rectal swab specimens for this study.

REFERENCES


